CTLA4 and melanoma: Another study targeting the CTLA4 pathway in 72 patients showed activity against melanoma BrM along with systemic responses, also with evidence of long-term survivors (26% overall survival at the 2-year timepoint).129 Knisely et al.130 found clinical benefits with the addition of ipilimumab, an anti-CTLA4 agent, to SRS in their study of 77 patients.